Elevation of the cyclin-dependent kinase (cdk) inhibitor, p27(kip1) is necessary for Interleukin (IL)-4-mediated growth arrest of human low grade astrocytoma (RTLGA) cells and occurs at 24 h of treatment. Pathways involved in IL-4 alteration of p27(kip1) are unknown, however. Here we investigated whether other cdk inhibitors contributed to the actions of IL-4 on RTLGA cells. By 12 h of IL-4 treatment, both cdk4 and cdk2 kinase activities against the retinoblastoma protein (pRb) were reduced and nuclear entry of pRb was prohibited. Twelve-hour cdk complexes contained elevated p21(waf1/cip1) but not p27(kip1), p15(ink4B) or p16(ink4A). IL-4 increased p21(waf1/cip1) but not p27(kip1) mRNA levels, and stimulated luciferase activity of a p21(waf1/cip1) promoter-luciferase reporter. In p53-mutant WITG3 cells, IL-4 did not alter p21(waf1/cip1) mRNA and promoter-luciferase activity or p27(kip1) protein, suggesting a need for functional p53. STAT6 phosphorylation by IL-4, however, occurred in both p53-mutant WITG3 and p53-functional RTLGA cells. Pre-treatment of RTLGA with anti-sense but not missense p21(waf1/cip1) oligonucleotide prior to IL-4: (a) restored cdk activities; (b) reduced cdk4-associated p21(waf1/cip1) levels; (c) prevented p27(kip1) elevation; and (d) reversed growth arrest. These results are the ®rst to suggest that p21(waf1/cip1) is essential for IL-4-mediated elevation of p27(kip1) and growth arrest of astrocytoma cells. Oncogene (2000) 19, 661 ± 669.
Introduction
Regulation of the cell cycle requires a coordinated series of both positive and negative signals. The enzymatic activities of cyclin-dependent kinases (cdks) and attendant cyclin proteins represent positive signals, while negative regulators are illustrated by the INK4 and CIP/KIP proteins (Morgan, 1995; Sherr, 1996; Draetta and Pagano, 1996; Harper, 1997) . INK4 proteins selectively combine with cdk4 and cdk6, contain ankyrin repeat sequences, and consist of p16(ink4a), p15(ink4b), p18(ink4c), and p19(ink4d) (Sherr and Roberts, 1995; Harper, 1997) . CIP/KIP inhibitors such as p27(kip1) and p21(waf1/cip1) are less selective and bind to a broader range of G 1 and mitotic cdk complexes (Xiong et al., 1993; Harper et al., 1993; Polyak et al., 1994a; Toyoshima and Hunter, 1994) . Accumulation of p21(waf1/cip1) occurs in cells undergoing dierentiation, senescence, or in response to DNA damage (Steinman et al., 1994; Noda et al., 1994; Hallevy et al., 1995; Dulic et al., 1994) . Levels of p27(kip1) increase during contact inhibition, mitogen deprivation, or G 1 /S blockade (Polyak et al., 1994b; Kato et al., 1994) .
Interleukin 4 (IL-4) represents a pleotrophic cytokine that stimulates or inhibits growth in a cell-type speci®c fashion (Puri, 1995; Paul, 1997; Howard et al., 1982) . IL-4 stimulates proliferation of T lymphocytes (Mitchell et al., 1989) and microglia (Suzumura et al., 1994) , but in astrocytes, IL-4 produces growth arrest in the G 1 phase of the cell cycle (Estes et al., 1993; Liu et al., 1997; Brodie et al., 1998) . The anti-mitogenic eects of have been demonstrated in human astroglial cell lines derived from non-neoplastic adult cerebral cortex and from low grade neoplasia (astrocytoma) (Barna et al., 1995) . Investigation of mechanisms involved in IL-4-mediated growth arrest of astrocytoma cells indicated that catalytic activity of cyclin E/cdk2 complexes decreased and p27(kip1) levels increased after 24 h of treatment (Liu et al., 1997) . Elevated p27(kip1) was readily detectable in total cell lysates as well as within immunoprecipitated cyclin E/cdk2 complexes and remained at supranormal levels for 24 h. In contrast, p21(waf1/cip1) levels were virtually undetectable after 24 h of IL-4 exposure and were not associated with cyclin E/cdk2 (Liu et al., 1997) . Pretreatment of cells with antisense (AS) but not missense (MS) p27(kip1) oligonucleotides prior to IL-4 treatment completely abolished p27(kip1) elevation and reversed the negative eects of IL-4 on cyclin E/cdk2 activity and G 1 progression. Thus results indicated that p27(kip1) was essential to the anti-mitogenic machinery of IL-4.
Interestingly, experimental animals bearing glial tumors co-implanted with cells engineered to produce IL-4 via viral vectors have shown signi®cantly improved survival compared to controls (Sampson et al., 1997; Wei et al., 1998; Benedetti et al., 1999) . Collectively, such data suggest that IL-4 may have a potential role in clinical brain tumor therapy but that mechanisms involved in the therapeutic eects of IL-4 on brain tumors may be quite complex (Tepper et al., 1992; Noz et al., 1998) .
From our previous results, it was not possible to deduce whether p27(kip1) represented the sole mediator by which IL-4 growth-arrested astrocytoma cells or whether other cdk inhibitors might be involved. The purpose of this study therefore was to address this issue by investigating the possible roles of cdk inhibitors in cell cycle events occurring prior to the marked elevation of p27(kip1) observed at 24 h of IL-4 treatment. Novel results presented herein show that: (a) IL-4 upregulates p21(waf1/cip1); and (b) p21(waf1/cip1) is necessary for subsequent elevation of p27(kip1), a relationship not previously reported, to our knowledge. Thus IL-4 blocks astrocytoma cycling at the G 1 /S interface by employing a dual inhibitor mechanism in which elimination of either p21(waf1/cip1) or p27(kip1) cancels IL-4 action and restores proliferation.
Results

Reduction of cyclin-dependent kinase activity against pRb substrate
The Rb protein is subject to phosphorylation by several cyclin-dependent kinases including cdk4 and cdk2. Previous studies indicated that IL-4 antagonized cdk2 activity late in G1 against a histone H1 substrate (Liu et al., 1997) , but eects on cdk2 or cdk4 against pRb substrates had not been established. Utilization of a GST-pRb substrate indicated that by 12 h of treatment, IL-4 reduced EGF-stimulated kinase activity of cdk4 by 51% (P50.01; n=5) (Figure 1a) , and cdk2 by 48% (P50.05; n=2) ( Figure 1b ) compared to EGF alone. Evaluation of pRb activity in RTLGA astrocytoma cells demonstrated that translocation to the nucleus was stimulated by EGF ( Figure 2a ) but in the presence of EGF+IL-4, translocation did not occur and pRb remained primarily cytoplasmic (Figure 2b ). Cytoplasmic pRb was characteristic of both untreated and IL-4 treated cells (Figure 2c ).
Cdk inhibitors associated with pRb kinases
In cdk4 and cdk2 complexes, p27(kip1) was present but unchanged by 12-h IL-4 treatment (Figure 3) . In contrast, IL-4 increased p21 (waf1/cip1) in both cdk4 and cdk2 complexes compared to EGF-treated or untreated cells (Figure 3) . No consistent changes in either p15(ink4b) or p16(ink4a) cdk inhibitors were detectable after IL-4 exposure (data not shown).
Examination of solubilized cdk4 and cdk2 complexes over time suggested that associated p21 (waf1/cip1) levels were dynamic and by 18 h of IL-4 treatment were no longer elevated (Figure 3 ). Interestingly, p27(kip1) levels appeared to show some increase in 18-h cdk4 complexes, an observation compatible with previous results indicating markedly increased p27(kip1) after 24 h of IL-4 treatment (Liu et al., 1997) . Current ®ndings suggested that IL-4 mediated a transient increase of p21 (waf1/cip1) prior to p27(kip1) elevation. 
Analysis of Cdk inhibitor mRNA
The increase in cdk-complex associated p21(waf1/cip1) after IL-4 treatment prompted investigation of possible transcriptional changes in inhibitor expression. A survey of p21(waf1/cip1) and p27(kip1) mRNA levels after 6, 12 and 18 h of IL-4 treatment suggested an approximately ®vefold increase in p21(waf1/cip1) mRNA at 12 h compared to b-actin but no change in p27(kip1) (Figure 4a ). The possible eects of IL-4 on p21(waf1/cip1) mRNA levels were then re-examined in comparison with cycloheximide which is known to increase p21 (waf1/cip1) mRNA (MacLeod et al., 1995) . Results indicated that p21(waf1/cip1) mRNA levels in RTLGA cells increased after 12-h treatment with IL-4 or cycloheximide when compared to expression of GAPDH (Figure 4b ). Levels of p27(kip1) mRNA were unchanged by either IL-4 or cycloheximide (data not shown).
To determine whether there was evidence for IL-4-mediated induction of p21(waf1/cip1) transcription, activation of a p21 promoter-luciferase reporter (WWP-Luc) by IL-4 was investigated. Introduction of WWP-Luc into RTLGA cells followed by IL-4 treatment increased luciferase activity by over eightfold compared to untreated cells ( Figure 4c ). As anticipated, cycloheximide had no eect on WWP-Luc activation (data not shown).
Cdk inhibitor changes in the presence of mutant p53
The eect of IL-4 on p21(waf1/cip1) mRNA levels was also examined in the WITG3 glioblastoma cell line which carries a homozygous p53 mutation, nonfunctional p53 protein, and is refractory to IL-4's anti-mitogenic eects (Barna et al., 1995; Toms et al., 1998) . In WITG3 cells, p21(waf1/cip1) mRNA levels were increased by cycloheximide, but not by IL-4 (Figure 4b ), while p27(kip1) levels were unaected by either (data not shown). The cycloheximide results are in keeping with earlier reports indicating a p53-independent mode of action thought to involve removal of a protein inhibitor acting either at transcriptional or post-transcriptional levels (Michieli et al., 1994; MacLeod et al., 1995) . Introduction of the WWP-Luc reporter into WITG3 cells yielded no luciferase activity with IL-4, suggesting that IL-4 was not eective in cells containing non-functional p53 ( Figure 4c ).
To verify that RTLGA cells contained functional wild-type p53, cells were transfected with a PG13-Luc luciferase reporter containing multiple wild-type p53 binding sites and treated with the DNA cross-linking agent, Cisplatin (5 ug/ml) (O'Connor et al., 1997). Luciferase activity increased by approximately 25-fold compared to untreated control, con®rming the presence of functional p53 in RTLGA. Introduction of a control luciferase reporter (MG15-Luc) containing mutated p53 binding sites yielded no activity (data not shown). In p53-mutant WITG3 cells, transfection of PG13-Luc followed by Cisplatin treatment produced no luciferase activity, con®rming previous ®ndings showing lack of p53 function in this cell line (Toms et al., 1998) .
Further investigation of WITG3 cells indicated that unlike RTLGA cells, 24 h treatment with IL-4 did not elevate p27(kip1) protein levels compared to actin ( Figure 5 ). This observation suggested that IL-4 activation of p21(waf1/cip1) might be linked to subsequent elevation of p27(kip1). Interestingly, WITG3 cells stimulated with EGF demonstrated a marked reduction in p27(kip1) ± a ®nding previously Figure 3 Increased p21(waf1/cip1) in cdk4 and cdk2 complexes after 12-h IL-4 treatment. Cdk inhibitors p21(waf1/cip1) and p27(kip1) were immunoblotted from solubilized, immunoprecipitated cdk4 and cdk2 complexes after 12 and 18 h treatments shown. Arrows=IL-4-associated increases in p21(waf1/cip1) at 12 h noted elsewhere in proliferating cells (Pagano et al., 1995; Coats et al., 1996) .
To determine whether an IL-4 signaling de®ciency could account for the discrepancy in IL-4 response between p53-functional and mutant cells, IL-4 activation of the STAT6 transcription factor was investigated. In both p53-mutant WITG3 and p53-functional RTLGA cells, 5-min treatment with IL-4 elicited tyrosine phosphorylation of STAT6 (Figure 6 ). IL-4 elicited phosphorylation in the presence or absence of EGF which alone did not alter STAT6 (Figure 6 ). Thus IL-4 signaling as represented by STAT6 phosphorylation was not impaired in p53-mutant WITG3 cells and could not account for the failure of IL-4 to increase p21(waf1/cip1) and p27(kip1).
Effects of antisense and missense oligonucleotides
The putative requirement for p21(waf1/cip1) in the IL-4 regulatory pathway was investigated by transfecting antisense (AS) p21(waf1/cip1) oligonucleotide into RTLGA cells before IL-4 treatment. AS but not missense (MS) p21(waf1/cip1) oligonucleotide restored EGF-stimulated cdk4 and cdk2 kinase activities against pRb substrate despite the presence of IL-4 (Figure 7a ). Levels of p21(waf/cip1) in 12-h cdk4 complexes following IL-4 treatment were reduced by AS but not by MS p21(waf1/cip1) oligonucleotide (Figure 7b ). Immunoprecipitation of p21(waf1/cip1) also con®rmed that the IL-4-mediated elevation at 12 h was blocked by AS but not by MS oligonucleotide (Figure 7c ). These results indicated that IL-4 elevation of p21(waf1/ cip1) was necessary for regulating pRb.
The question next investigated was whether p21(waf1/cip1) was also necessary for IL-4 mediated elevation of p27(kip1), as implied by ®ndings in p53-mutant WITG3 cells. RTLGA cells were pre-treated with antisense or missense p21(waf1/cip1) oligonucleotides prior to IL-4 treatment. Levels of p27(kip1) were then inspected in 24-h cyclin E/cdk2 complexes and in total cell lysates where previous studies had noted p27(kip1) elevation (Liu et al., 1997) . Results indicated that AS but not MS p21(waf1/cip1) oligonucleotide abolished the stimulatory eects of IL-4 on p27(kip1) levels in both cyclin E complexes ( Figure 8a ) and total cell lysates (Figure 8b ).
Since removal of p27(kip1) had been shown to reverse IL-4-mediated growth arrest (Liu et al., 1997) , it seemed likely that removal of p21(waf1/cip1) upon which p27(kip1) depended, should also thwart IL-4's anti-mitogenic action. This issue was examined using BrdU incorporation as an indicator of DNA synthesis ( Figure 9 ). Percentage BrdU incorporation in RTLGA cells exposed to EGF alone was 22.7+1.4% (n=4), in line with previous results (Liu et al., 1997) . In cells exposed to EGF+IL-4, BrdU incorporation was signi®cantly reduced (5.6+1.1%, n=3) (P50.01 compared to EGF alone) and remained so after pretreatment with MS p21(waf1/cip1) oligonucleotide (4.6+0.3, n=2). Pre-treatment with AS p21(waf1/ cip1), however, reversed the eect of IL-4 on EGF, yielding BrdU incorporation of 21.1+0.3% (n=2) (P50.01 compared to MS p21(waf1/cip1)). Thus data indicated that IL-4-mediated p27(kip1) elevation and growth inhibition were both dependent upon prior activation of p21(waf1/cip1).
Discussion
These studies are the ®rst to report a cell cycle regulatory circuit in which changes in p27(kip1) levels leading to growth arrest are themselves dependent upon prior activation of p21(waf1/cip1). Harper (1997) has observed that cdk inhibitor expression may be highly cell type-speci®c in vivo. Brain tissue is rich in p27(kip1) (Nakayama et al., 1996) , and glial precursors developing along astrocytic pathways show upregulation of p27(kip1) . The RTLGA astrocytoma cells used in our studies also demonstrated p27(kip1) which could be raised even further by IL-4. One of the biological functions proposed for p27(kip1) is that of a`restriction point' regulator which controls access to cell cycling or dierentiation (Ko and Polyak, 1995) . Cells from p27(kip1)-de®cient mice show inappropriate proliferation, resulting in increased body size (Nakayama et al., 1996; Fero et al., 1996; Kiyokawa et al., 1996) . Precursor cells from the central nervous system of such mice dierentiate more slowly than those of normal counterparts (Casaccia-Bonne®l et al., 1997). These ®ndings imply that extracellular factors like IL-4 which promote p27(kip1) elevation may promote acquisition of a dierentiated phenotype. Evidence supporting this concept stems from studies showing that IL-4 enhances glial cell production of glutamine synthetase and other proteins associated with dierentiated astrocytes (Brodie and Goldreich, 1994; Brodie et al., 1998) .
There is ample evidence for cooperation of cdk inhibitors in regulating G 1 progression. TGF-bmediated growth arrest of mink lung epithelial cells is associated with induction of the p15(Ink4B) cdk inhibitor which is proposed to displace p27(kip1) from cdk4 to cdk2 complexes (Hannon and Beach, 1994; Reynisdottir et al., 1995) . Total p27(kip1) levels do not appreciably increase in such cells (Reynisdottir et al., 1995) . Our data show early and transient increases in p21(waf1/cip1) associated with cdk4 and cdk2 complexes after IL-4 treatment but no evidence for increased p15(ink4B). Leukemic B cells growth-arrested by IL-4 also show no change in p15(Ink4B) (Blanchard et al., 1997) . The current results together with those of our previous study are compatible with a dual inhibitor model of IL-4 action in which early G1 kinase, cdk4 is targeted by p21(waf1/cip1) and later acting cdk2 by p27(kip1) (Liu et al., 1997) . Removal of either cdk inhibitor, as shown by our antisense results, eectively destroys the model and restores proliferation. It should be noted, however, that cell cycle regulation by p21(waf1/cip1) and p27(kip1) appears quite complex and possibly cell type-speci®c, as shown by a recent report indicating that ®broblasts require both cdk inhibitors for normal cyclin D-cdk activity (Cheng et al., 1999) .
Pathways by which IL-4 utilizes p21(waf1/cip1) to control astrocytoma p27(kip1) levels have not been established. Regulation of p27(kip1) may occur via transcriptional and/or posttranscriptional mechanisms (Agrawal et al., 1996; Hengst and Reed, 1996; Millard et al., 1997; Kwon et al., 1997) . Posttranscriptional control of p27(kip1) has been shown to involve degradation by the ubiquitin-proteasome pathway, which may be more active in highly aggressive tumors (Pagano et al., 1995; Loda et al., 1997) . Our data suggest that IL-4 regulates astrocytoma p27(kip1) at posttranscriptional levels since we failed to ®nd any evidence of altered p27(kip1) mRNA. We also noted sharply decreased p27(kip1) protein in the IL-4-unresponsive WITG3 glioblastoma cell line after EGF stimulation, suggesting a capacity for rapid degradation of p27(kip1) in these cells. Whether this process would antagonize the eects of IL-4 on p27(kip1) in WITG3 has not yet been determined. It is clear, however, that the failure of WITG3 cells to increase p21(waf1/cip1) in response to IL-4 represents a critical defect preventing subsequent elevation of p27(kip1) and growth arrest.
Our results suggest that functional p53 may be required for the IL-4 model of growth control. The p53 tumor suppressor protein mediates growth arrest in response to DNA damage by functioning as a transcriptional activator of cell cycle checkpoint-related genes, among which is p21(waf1/cip1) (El Deiry et al., 1993; Waldman et al., 1995; Levine, 1997; Agarwal et al., 1998) . Activation of p21(waf1/cip1), however, may occur independent of p53 control (MacLeod et al., 1995; Michieli et al., 1994; Zeng and El-Deiry, 1996) . Although we have established that IL-4 unresponsive WITG3 cells contain homozygous, non-functional mutant p53, other anomalies may exist to complicate interpretation of IL-4 results in such cells (Toms et al., 1998) . For example, ectopic expression of murine double minute 2 (MDM2) has been shown to overcome TGF-binduced growth arrest in a p53-independent fashion (Sun et al., 1998) . Ampli®cation and overexpression of MDM2 have been reported in malignant brain tumors (Reifenberger et al., 1993) . Previous ®ndings clearly indicate that loss of the IL-4 receptor a chain, a de®ciency noted in some glioblastoma lines, abrogates IL-4 responsiveness (Barna et al., 1995) . Further studies will seek to determine whether overexpression of mutant p53 in IL-4 responsive astrocytes antagonizes the eects of IL-4 on p21(waf1/cip1), p27(kip1), and cell cycling. More extensive investigation is needed however, to identify other genes conferring resistance to IL-4-mediated growth arrest in glioblastoma cells.
Our results also indicate that IL-4 signal transduction via STAT6 activation occurs in both growth-arrest sensitive RTLGA and refractory WITG3 cells. STAT6, a member of the STAT group of signaling proteins, is expressed constitutively in the cytoplasm of most cells and is essential for many of the biological actions of IL-4 (Takeda et al., 1996; Shimoda et al., 1996; . Stimulation with IL-4 activates Jak tyrosine kinases to phosphorylate STAT6, after which STAT6 undergoes homodimerization and translocates to the nucleus (Damell, 1997; Takeda et al., 1997) . STAT6 binding sites have been found in promoter regions of several IL-4-inducible genes (Kotanides and Reich, 1996; Lu et al., 1997) . Binding sites for STAT1, another member of the STAT family, have been detected within the p21(waf1/cip1) promoter region, and activation of STAT1 and p21(waf1/cip1) are linked in some cells growth-arrested by EGF or ®broblast growth factor (Chin et al., 1996; Johnson et al., 1998) . Interestingly, a DNA sequence recognized by STAT1 (TTC{N 3 }GAA) can also be bound by STAT6 (Seidel et al., 1995) . That IL-4 signals STAT6 phosphorylation in both IL-4 responsive RTLGA and unresponsive WITG3 cells in our studies, however, suggests that activation of STAT6 alone is not sucient for growth arrest. Indeed, lymphocytes from STAT6-null mice show highly elevated p27(kip1) compared to normals (Kaplan et al., 1998) . Thus although increased p27(kip1) has been associated with the anti-proliferative eects of IL-4 in both astrocytes and hematopoietic cells (Liu et al., 1997; Blanchard et al., 1997) , it is not yet clear what role STAT6 holds in this process.
In summary, our data indicate that IL-4 mediates G 1 growth arrest in astrocytoma cells through a series of steps requiring induction of p21(waf1/cip1) followed by elevation of p27(kip1). IL-4 suppression of pRb phosphorylation, a critical regulatory point in G 1 cell cycle progression, represents a p21(waf1/cip1)-dependent step. Further, the subsequent elevation of p27(kip1) shown previously to be necessary for both suppression of cyclin E/cdk2 activity and IL-4-mediated growth arrest is also p21(waf1/cip1)-dependent (Liu et al., 1997) . Finally, results indicate that despite evidence of competent IL-4 signal transduction, p53-mutant WITG3 cells failed to show p21(waf1/cip1) induction, p27(kip1) elevation, or growth arrest after IL-4 treatment. Taken together, results from p53-mutant WITG3 and anti-sense p21(waf1/cip1)-treated RTLGA cells point to a critical role for p21(waf1/cip1) in the anti-mitogenic eects of IL-4 on astrocytoma cells.
Materials and methods
Reagents and cell lines
Recombinant IL-4 was a generous gift from Dr Satwant Narula, Schering-Plough Research Institute (Kenilworth, NJ, USA). EGF was obtained from GIBCO-BRL (Grand Island, NY, USA). Antibodies speci®c for human cyclins (D1, D2, E), p15(ink4B), p16(ink4A), p21(waf1/cip1), p27(kip1), cdk2, cdk4, STAT6, and phosphotyrosine (PY) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Antibody to human pRb was obtained from Pharmingen (San Diego, CA, USA). The non-immortal RTLGA culture was derived from low grade astrocytoma and aliquots of low passage have been cryogenically stored as described (Barna et al., 1995) . The WITG3 line was derived from glioblastoma multiforme and has been described (Toms et al., 1998) . Monolayers were maintained for 2 days in RPMI 1640 medium containing 2% FBS before initiation of treatment with EGF (10 ng/ml), IL-4 (10 ng/ml), cycloheximide (1.0 mg/ml) or combinations thereof. Antisense (AS) (GS4931) and mismatch (MS) (GS5207) p21(waf1/cip1) propyne-modi®ed oligonucleotides were generously provided by Gilead Sciences (Foster City, CA, USA). Oligonucleotide sequences were: (GS4931) 5'-UCC GCG CCC AGC UCC; and (GS5207) 5'-UCC GCC CGC AGU CCC.
Immunocytochemistry
Coverslip cultures were washed in cold phosphate-buered saline (PBS) and ®xed in ice cold 95% ethanol as described (Estes et al., 1993) . Coverslips were incubated with antibody to pRb (1 : 100) in PBS +5% normal goat serum. After additional washing in PBS, coverslips were incubated with uorescein isothiocyanate-conjugated goat antibody to murine IgG (KPL, Gaithersburg, MD, USA) (1 : 100), washed and mounted in Vectashield (Vector Laboratories, Burlingame, CA, USA). For analysis of DNA synthesis, BrdU labeling (Boehringer-Mannheim, Indianapolis, IN, USA) was carried out as described (Liu et al., 1997) .
Treatment with anti-sense oligonucleotides
Monolayers at 50% con¯uence were incubated for 18 h with 30 nM AS or MS p21(waf1/cip1) oligonucleotide and 2.5 mg/ ml GS2888 cytofectin (Gilead) in Opti-MEM +10% FBS (GIBCO). Medium was aspirated and fresh medium containing IL-4 with or without EGF was added. Cells were harvested for analysis of pRb kinase activity and cdk4-associated p21(waf1/cip1) at 12 h, and for p27(kip1) content of total cell lysates and cyclin E complexes at 24 h.
Immunoblotting analysis
Lysates were prepared from PBS-washed cells and electrophoresed in 7.5 or 10% SDS polyacrylamide gels as previously described (Liu et al., 1997) . Proteins were transferred onto nitrocellulose membranes (Bio-Rad, Richmond, CA, USA) overnight and membranes were blocked with 5% skim milk in Tris-buered saline, containing 0.1% Tween 20 (TBS-T). Primary antibodies were diluted in TBS-T containing 2.5% skim milk and incubated with membranes for 1 h. For blotting with PY antibody, membranes were blocked overnight with 7.5% bovine serum albumin (Sigma) in TBS-T containing 200 mM NaOV 3 and 50 mM NaF. After further washing and exposure to appropriate secondary antibodies, membranes were incubated with ECL reagents (Amersham, Arlington Heights, IL, USA). Proteins were visualized by chemiluminescence after exposure of membranes to Hyper®lm (Amersham) for 0.5 ± 5 min.
Kinase assays
Lysates for pRb kinase assays were prepared for immunoprecipitation (IP) as previously described (Liu et al., 1997 ). After 15 s sonication64, lysates were incubated with 2 mg antibody against cdk4 or cdk2 for 1 h on ice. Protein ASepharose (3 mg per tube in 30 ml) (50% vol/vol) was then added, the mixture was rotated for 1 h, and beads were pelleted. Half of the IP samples were solubilized by boiling in Laemmli sample buer for identi®cation of components by immunoblotting. Phosphorylation of pRb substrate was determined by incubating the remaining half of IP samples on beads for 30 min at 308C in kinase assay buer containing 50 mM cold ATP, 5 mCi [ 32 P]g-ATP, and 0.5 mg Rb protein.
The reaction was terminated by boiling in Laemmli sample buer. Substrates were identi®ed by resolution in 7.5% SDS polyacrylamide gel followed by Coomassie blue staining, and autoradiography. Radiolabeled bands were further analysed by imaging using ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA).
RNA analyses
Total cellular RNA was extracted by the acid guanidiniumphenol-chloroform method. Denatured total RNA (20 mg) was electrophoresed through 1.0% agarose gel containing 2.2 M formaldehyde and formamide, and then was transferred to a GeneScreen membrane, ultraviolet cross-linked and baked as previously described (Kondo et al., 1996) . The following 32 P-dCTP-labeled cDNA probes were used for hybridization: p21(waf1/cip1) (gift from B Vogelstein); p27(kip1) (gift from J Massague) and human GAPDH (Oncogene Science). Membranes were washed with the ®nal wash in 0.26SSC, 0.1% SDS at 658C. Autoradiography was performed using a phosphorimager (Molecular Dynamics). For preliminary time-study experiments, RNA levels were surveyed over time using reverse-transcribed (RT) ± PCR (Perkin Elmer-Cetus, Norwalk, CT, USA). Primers were speci®c for: p21(waf/cip1) (El Deiry et al., 1993) (0.099 kb); p27(kip1) (Lois et al., 1995) (0.5 kb); and b-actin (0.84 kb) (Clontech). Products were ampli®ed by PCR using 30 cycles of denaturation at 948C645 s, annealing at 608C645 s, and primer extension at 728C62 min. PCR products were photographed and compared to molecular weight markers after electrophoresis in 2% agarose gels and ethidium bromide staining.
Luciferase assay
The luciferase reporter plasmids PG13, MG15, and WWPLuc (gifts from B Vogelstein) have been described (Kern et al., 1992; El-Deiry et al., 1995) . PG13 contains wild-type and MG15 contains mutant p53 binding sequences (Kern et al., 1992) . The WWP-Luc construct contains a 2.4 kb segment of the p21(Waf1/Cip1) promotor region (El-Deiry et al., 1995) . A blank luciferase plasmid (Clontech) was also used as a negative control. WITG3 and RTLGA cells were transiently transfected with luciferase reporter plasmids as described previously (Toms et al., 1998) . Cells were exposed to medium alone, Cisplatin (5 mg/ml), or IL-4 (10 ng/ml) for 6 ± 24 h, lysed, and analysed for protein content and luciferase activity. Luminometry readings were corrected for protein concentration and normalized to data from cells transfected with control plasmid and exposed to medium alone as described (Toms et al., 1998) .
Abbreviations AS, antisense; BrdU, bromodeoxyuridine; cdk, cyclindependent kinase; EGF, epidermal growth factor; FBS, fetal bovine serum; IL-4, interleukin 4; IP, immunoprecipitation; MS, missense; PBS, phosphate-buered saline; pRb, retinoblastoma protein; RT ± PCR, reverse-transcribed polymerase chain reaction; SDS, sodium dodecyl sulfate; STAT, signal transducers and activators of transcription; TGF-b, transforming growth factor beta.
